Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025

Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation. Merck’s Keytruda (pembrolizumab) remained pharma’s No. 1 brand in FY2025 with $31.7 billion in sales . But it is no longer the industry’s top-selling medicine at the molecule level. Lilly’s tirzepatide franchise, spanning Mounjaro ($22.965 billion) and Zepbound ($13.542 billion) , reached roughly $36.5 billion in 2025 revenue, while Novo Nordisk’s semaglutide franchise, counting Ozempic, Wegovy and Rybelsus together, reached roughly $34.5 billion. Merck is still showing muscle. Keytruda grew 7% in 2025 , and the company is still extending the franchise with…

Merck’s Keytruda (pembrolizumab) remained pharma’s No. 1 brand in FY2025 with $31.7 billion in sales. But it is no longer the industry’s top-selling medicine at the molecule level. Lilly’s tirzepatide franchise, spanning Mounjaro ($22.965 billion) and Zepbound ($13.542 billion), reached roughly $36.5 billion in 2025 revenue, while Novo Nordisk’s semaglutide franchise, counting Ozempic, Wegovy and…

The post Pharma 50: Keytruda holds the top brand slot, but tirzepatide and semaglutide have already passed it at the molecule level in FY2025 appeared first on Drug Discovery and Development.